Technical Analysis for ARVN - Arvinas, Inc.

Grade Last Price % Change Price Change
grade B 21.98 -0.50% -0.11
ARVN closed down 0.5 percent on Wednesday, February 20, 2019, on 82 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical ARVN trend table...

Date Alert Name Type % Chg
Feb 20 Calm After Storm Range Contraction 0.00%
Feb 20 Inside Day Range Contraction 0.00%
Feb 20 Wide Bands Range Expansion 0.00%
Feb 20 Overbought Stochastic Strength 0.00%
Feb 19 Bearish Engulfing Bearish -0.50%
Feb 19 Slingshot Bullish Bullish Swing Setup -0.50%
Feb 19 Wide Range Bar Range Expansion -0.50%
Feb 19 New 52 Week High Strength -0.50%
Feb 19 Upper Bollinger Band Walk Strength -0.50%
Feb 19 Outside Day Range Expansion -0.50%

Older signals for ARVN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
  • Earnings date: ???
Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Biopharmaceutical Biology Diseases Genetics Androgen Receptor Metabolism
Is ARVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 7 Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium
Feb 4 Evolus leads healthcare gainers; Fortress Biotech and Check-Cap among losers
Feb 1 Protein Degradation: Finally, A Way To Treat 'Undruggable' Diseases?
Jan 7 5 Stocks To Watch For January 7, 2019
Jan 5 Arvinas on go with early-stage study of ARV-110 in prostate cancer
Jan 4 Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer
Dec 8 Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
Dec 4 Midday Gainers / Losers
Nov 20 Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference
Oct 23 Arvinas to Present at Two Protein Degradation Conferences
See more ARVN news...
Indicators
Indicator Value
52 Week High 25.6
52 Week Low 10.19
Average Volume 129,069
200-Day Moving Average 0.0
50-Day Moving Average 16.9096
20-Day Moving Average 19.651
10-Day Moving Average 21.631
Average True Range 1.6064
ADX 41.47
+DI 26.4564
-DI 12.4191
Chandelier Exit (Long, 3 ATRs ) 20.7808
Chandelier Exit (Short, 3 ATRs ) 20.6542
Upper Bollinger Band 24.2951
Lower Bollinger Band 15.0069
Percent B (%b) 0.75
BandWidth 47.265788
MACD Line 1.7119
MACD Signal Line 1.5004
MACD Histogram 0.2115
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.22
Resistance 3 (R3) 24.22 23.47 23.84
Resistance 2 (R2) 23.47 22.90 23.47 23.72
Resistance 1 (R1) 22.73 22.55 23.10 22.73 23.59
Pivot Point 21.98 21.98 22.17 21.98 21.98
Support 1 (S1) 21.24 21.41 21.61 21.24 20.37
Support 2 (S2) 20.49 21.06 20.49 20.24
Support 3 (S3) 19.75 20.49 20.12
Support 4 (S4) 19.75